Current Status on PPI in Japan

Satoshi MIKI

A Board Member of

General Incorporated Association PPI JAPAN



3rd ASIA-PACIFIC PATIENTS CONGRESS

af

RECOVERING TOGETHER THROUGH COMPASSION, INSIGHT & CO-CREATION

General Incorporated Association PPI JAPAN



Dr. Masaru IWASAKI, Chief Executive Officer

Board Member	Masaru IWASAKI	Academia
	Shun EMOTO	Patient Advocate, Rare Disease
	Naomi SAKURAI	Patient Advocate, Cancer
	Naoko SO	НСР
	Satoshi MIKI	Pharma Industry
	Kazuhiko MORI	Former MHLW General Councillor for Pharmaceutics
Auditor	Ikuko YAMAGUCHI	Patient Advocate

Membership

36 regular members

1 associate member


7 corporate support members

(As of Nov. 12)

- Established as a legal entity in November 2019
- Joined in EUPATI National Platform representing Japan in April
 2020 and the MOU with EUPATI signed in November 2020
- Promote mutual understanding and collaboration between patient groups, patient support groups, the general public, and industry-government-academia while digging up the needs of related parties through our policy based on careful communication
- Formulate our business plan and aim to become a parent body that realizes true "industry-patient-government-academia" collaboration

Practical PPI activities in Japan

- 1. Health Authority:
 - PMDA issued "Guidance on Patient Participation" on Sep. 7, 2021
 - English version has become available since Nov. 2, 2021 (https://www.pmda.go.jp/files/000243407.pdf)



2. Academia

- JCOG (Japan <u>Clinical Oncology Group</u>: the largest Japanese cooperative group with190 active participating institutions, funded primarily by the National Cancer Center Research and Development Fund) has been and is running "Patient and Public Involvement Committee" since 2018.
- 3. Industry
 - Pfizer R&D Japan G.K. is actively working for Patient Centricity / Patient & Public Involvement (PPI).

JCOG PPI Seminars

1st seminar held on Nov. 17, 2019
2nd seminar held on Feb. 6, 2021
3rd seminar held on Sep. 4, 2021
4th seminar (advanced course) due in early 2022

- Opinion Exchange Meetings between disease-oriented subgroups and patient advocates
- Disclosure of Pfizer Clinical Trial information & trial site information on the company web site
- Sharing of Pfizer Clinical Trial results with pts. who participated in the clinical trial together with Pfizer thanking letter
- Workshop to reflect pts' voices onto clinical trials
 - Pt. journey workshop
 - Pt. insight workshop

PPI Japan's progress in 2021

- 1. Improvement of utilization of the Japanese translated version of "EUPATI Toolbox"
 - "Table of Contents" sorted for users of the EUPATI Toolbox released on the renewed PPI JAPAN Home Page on Sep. 13, 2021
- 2. Creation of original contents and reference guide of already available local tools & information on Medicine Development in Japanese
 - Original PPI contents in Japanese under preparation
 - Reference guide of already available local tools & information on Medicine Development in Japanese under preparation
- 3. Information dissemination to promote the enlightenment of patient and public involvement
 - Dialogue with PPI JAPAN members: web meeting once every two months
 - 1st event held on August 30
 - 2nd event held on Nov. 1
 - PPI JAPAN seminar : "Learn about PPI activities in Japan" as webinar once every two months or quarterly
 - 1st seminar held on Sep. 27
 - Recent experiences and challenges on PPI activities at Pfizer R&D Japan G.K.
 - 2nd seminar due on Jan. 31, 2022
 - PMDA (<u>P</u>harmaceuticals and <u>M</u>edical <u>D</u>evices <u>Agency</u>) will share their "Guidance on Patient Participation" and related experiences.
 - AMED (Japan Agency for Medical Research and Development) will share their PPI activities and general policy.

Thank you for your attention!

